CTLA4 and neoplasm: ICIs enhance anti-tumor immune responses by blocking immune checkpoint proteins that inhibit T cell function, such as cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death protein 1 (PD-1) (1).